Oncology Nursing Society Foundation Josh Gottheil Memorial Bone Marrow Transplant Career Development Awards Awards: Four $2,000 awards and plaques. Purpose: To support a professional registered nurse for meritorious practice in BMT nursing by providing financial assistance to attend a continuing education program(s) that will further the nurses' professional goals, or to supplement tuition in a bachelors or masters program. Selection Criteria: Currently employed as a registered nurse working in bone marrow transplantation with a minimum of 75% time devoted to patient care, or in the position of nurse manager, nurse practitioner, or clinical nurse specialist with BMT patient population or a BMT coordinator. Two or more years in BMT nursing practice prior to application due date. An individual cannot receive this award more than one time. Application deadline: December 1, 2008
ONS Foundation 125 Enterprise Drive Pittsburgh, PA 15275 866-257-4ONS 412-859-6100 877-369-5497 (toll free fax) 412-859-6163 (fax) E-mail: foundation@ons.org Web site: www.onsfoundation.org
Fanconi Anemia Research Fund Program Announcement: Head And Neck Carcinogenesis Key Dates Release Date: July 1, 2008 Application Submission Date: Ongoing Peer Review Dates: Ongoing Earliest Anticipated Start Date: Ongoing Summary Fanconi anemia is a rare hereditary disease characterized by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS) and acute non-lymphocytic leukemia (AML), squamous cell carcinoma of the head and neck, and cellular hypersensitivity to cross linking agents. The function of the proteins is largely unknown, but many of them form complexes with each other and in one canonical “pathway” seven or eight of the known Fanconi anemia (FA) proteins bind together in a nuclear complex, a complex apparently required for the monoubiquitination of two of the three proteins not found in the core complex, FANCD2 and FANCI. Once this occurs, FANCD2 and FANCI translocate to damage-induced nuclear foci containing BRCA1, BRCA2 and Rad51. The functions of FANCD2 and FANCI in these nuclear complexes are unclear. Although more than 90% of the research in this field focuses on mechanisms of genotoxicity, a goal of the Fanconi Anemia Research Fund is to encourage investigative approaches dealing with the tissuespecific issues of the FA phenotype. Some have argued that because hypersensitivity to genotoxic stress is a feature of all somatic cells in FA, tissue-specific outcomes (specific epithelial malignancies and bone marrow failure, for example) are less likely to be related simply to genetic instability than to other functions of the protein. In fact, multiple biochemical functions have been ascribed to some of the FA proteins and, in some cases, these functions are cytoplasmic and not nuclear. The role of the Fanconi anemia proteins in protecting normal individuals against sporadic head and neck cancers is entirely unknown. The natural course of the disease in FA patients is unique. The onset of head and neck cancers in patients with Fanconi anemia (age 18-40) is decades earlier than in non-FA patients with this type of cancer and, unlike non-FA patients, the majority of such patients are neither tobacco smokers nor alcohol drinkers. The management of FA patients with this malignancy is also challenging. For example, FA patients may experience potentially lethal toxic effects from radiation and chemotherapy doses conventionally prescribed to patients with head and neck cancers. Therefore, clinical management is limited to surgical approaches and less-than-fully tested pharmacologic modalities that do not lead to DNA damage. This funding opportunity will use the investigator-initiated award mechanism to support work focused on the molecular pathogenesis, diagnosis, and treatment of head and neck squamous cell carcinoma in patients with FA. We expect that the nature and scope of the proposed research will vary from application to application. We expect that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received. Eligible Applications The goal of this initiative is to foster studies on the molecular pathogenesis, diagnosis and treatment of head and neck cancers in patients with Fanconi anemia. Applications focusing primarily on hematopoietic malignancies, bone marrow failure, developmental anomalies, endocrinopathies, or general functions of the FA proteins in DNA damage and repair responses will not be accepted for review under this RFA. Applications from the following will be considered: Eligible domestic and foreign institutions/organizations, including for-profit or nonprofit, public or private, units of state and local governments, and eligible agencies of the federal government. Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Applicants may submit only one application. Content and Form of Application Submission Applications must be prepared using the most current Fanconi Anemia Research Fund (Fund) research grant application instructions and forms.
Fanconi Anemia Research Fund, Inc. 1801 Willamette Street, Suite 200 Eugene, OR 97401 Telephone: 541-687-4658 Family Support Toll-Free Line (in United States): 1-888-FANCONI (888-326-2664) Fax: 541-687-0548 E-mail: info@fanconi.org
Grant ApplicationsPrincipal investigators, post-doctoral fellows or grant coordinators may request a grant application packet. Grant proposals may be submitted at any time throughout the year.Contact the Fund at info@fanconi.org or by telephone at 1-541-687-4658 or by fax at 1-541-687-0548 to request an application packet. The packet contains application forms and guidelines, conditions of award, and criteria for peer review.Researchers should direct questions or concerns about the grant application process to Mary Ellen Eiler, Executive Director. All project proposals are subject to rigorous peer review. Final funding decisions are made by the Fund's Board of Directors.
Research PrioritiesResearch priorities are set jointly and reviewed annually by the Board of Directors and the Scientific Advisory Board. Our current research priorities are as follows: * To identify the FA genes and to understand their functions and their roles in producing the hematologic and non-hematologic manifestations of Fanconi anemia. * To facilitate clinical research studies to improve FA diagnosis, therapy, and disease prevention. * To determine the causes of bone marrow failure in Fanconi anemia, and to develop treatments to prevent, treat or cure bone marrow failure. * To define the molecular pathogenesis of clonal evolution, carcinogenesis, and leukemogenesis in Fanconi anemia, and to develop strategies for the early detection and prevention of leukemia and other cancers. * To support the creation of shared resources for the international Fanconi anemia research community.
Fanconi Anemia Research Fund, Inc.1801 Willamette Street, Suite 200Eugene, OR 97401Telephone: 541-687-4658Family Support Toll-Free Line (in United States):1-888-FANCONI (888-326-2664)Fax: 541-687-0548E-mail: info@fanconi.org
1
